Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics

[1]  Youqing Wang,et al.  Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019 , 2022, Frontiers in Public Health.

[2]  M. Gaze,et al.  Renal protection during 177lutetium DOTATATE molecular radiotherapy in children: a proposal for safe amino acid infusional volume during peptide receptor radionuclide therapy , 2021, Nuclear medicine communications.

[3]  M. Mitterhauser,et al.  Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer , 2021, Current oncology.

[4]  K. Rahbar,et al.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.

[5]  K. Herrmann,et al.  The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. , 2021, Nuclear medicine and biology.

[6]  H. Wester,et al.  Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors? , 2021, EJNMMI Radiopharmacy and Chemistry.

[7]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[8]  O. Bavi,et al.  Potential effective inhibitory compounds against Prostate Specific Membrane Antigen (PSMA): A molecular docking and molecular dynamics study. , 2021, Archives of biochemistry and biophysics.

[9]  D. V. van Gent,et al.  Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  R. Schibli,et al.  Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  T. Çermik,et al.  Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands , 2019, The Journal of Nuclear Medicine.

[12]  Daniela A. Ferraro,et al.  First Clinicopathologic Evidence of a Non–PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands , 2019, The Journal of Nuclear Medicine.

[13]  P. Meyer,et al.  [177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography , 2019, Pharmaceuticals.

[14]  R. Kuefer,et al.  Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis , 2018, Front. Oncol..

[15]  S. Fanti,et al.  68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  U. Haberkorn,et al.  The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[17]  J. Konvalinka,et al.  Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities , 2016, The FEBS journal.

[18]  M. Pomper,et al.  Prostate-specific membrane antigen as a target for cancer imaging and therapy. , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[19]  J. Konvalinka,et al.  Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II. , 2015, Journal of medicinal chemistry.

[20]  J. Konvalinka,et al.  Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III , 2009, The FEBS journal.

[21]  Christof Baltes,et al.  A portable albumin binder from a DNA-encoded chemical library. , 2008, Angewandte Chemie.

[22]  J. Konvalinka,et al.  Biochemical characterization of human glutamate carboxypeptidase III , 2006, Journal of neurochemistry.

[23]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Knorr,et al.  Radionuklidtherapie des Prostatakarzinoms mittels PSMA-Lutetium , 2016, Der Urologe.